Intraductal Secretin Stimulation Test: What Is the Proper Collection Time?

• Status: Recruiting
• Trial end date: 2022-09-01
• Target enrollment: 0
• Participant gender: All

Summary

The aim is to evaluate the peak secretory flow rates and bicarbonate concentrations as determined by a 30 minute intraductal secretin stimulation test in patients with a low likelihood of pancreatic pathology and to compare these data to those obtained from our historical patients with suspected chronic pancreatitis. These will be patients in which inadvertent pancreatic cannulation occurs during therapeutic endoscopic retrograde cholangiopancreatography (ERCP) for biliary indications . All study subjects will receive a 5 day follow-up phone call. Enrollment goal is 36 subjects.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Indiana University
• Treatments: Secretin

Criteria

Inclusion Criteria:

1. Male or female patients ≥ 18 years of age referred to Indiana University Health, University Hospital for ERCP for a biliary indication, at the discretion of the treating MD (e.g. suspected common bile duct stone, initial post-liver transplant evaluation, suspected or confirmed cholangiocarcinoma, suspected primary sclerosing cholangitis -- see exclusion criterion #12)

Exclusion Criteria:

1. Pregnant woman or breast feeding

2. Age <18 years

3. Patient unable to give informed consent

4. Patient with a history of pancreatic surgery

5. Patient with a history of pancreatic cancer

6. Patient with a history of acute or chronic pancreatitis

7. Patient with radiographic evidence of acute or chronic pancreatitis on CT, MRCP, or EUS

8. Patient with a current or prior history of average daily alcohol consumption of greater than 60 g per day for more than 2 years

9. Patient with a history of cigarette smoking greater that 20 pack-years

10. Patient with a history of pancreas divisum

11. Evidence of chronic pancreatitis on pancreatogram during ERCP

12. ERCP for an isolated biliary indication with previous biliary sphincterotomy or for biliary stent exchange, when pancreatic entry should easily be avoided by the endoscopist.

13. History of allergy or adverse reactions to secretin